King of Prussia, PA, United States of America

Zhonghui Lu

This inventor holds 19 USPTO granted patents and 2 published patent applications and 13 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Bristol-Myers Squibb Compnay, Bristol-Myers Squibb Pharma Company. Active years: 2004-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhonghui Lu. Retrieved from https://idiyas.com/inventor/zhonghui-lu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 19 

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.5

ph-index = 6

Forward Citations = 80(Granted Patents)


Location History:

  • Wilmington, DE (US) (2004 - 2007)
  • King of Prussia, PA (US) (2009 - 2021)

Company Filing History:


Years Active: 2004-2021

Loading Chart...
Loading Chart...
Areas of Expertise:
RORγ Modulators
Heterocyclic Compounds
JAK3 Inhibitors
TNF Inhibitors
Cyclic Amino Acids
Barbituric Acid Derivatives
Matrix Metalloproteinases
Glucocorticoid Receptor
Azaindazoles
Sulfone Compounds
Cyclic Hydroxamic Acids
Tricyclic Heterocycles
19 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Zhonghui Lu

Introduction

Zhonghui Lu is a distinguished inventor based in King of Prussia, PA, known for his significant contributions to the field of pharmaceuticals and biotechnology. With a remarkable portfolio comprising 19 patents, Lu has made notable advancements in the modulation of critical biological pathways, focusing particularly on autoimmune and inflammatory disorders. His work emphasizes the design and application of innovative molecular compounds that have implications for therapeutic treatments.

Latest Patents

Among Zhonghui Lu's latest patents are the innovative RORγ modulators, which are detailed in his recent applications. These modulators, defined by specific formulas, encompass stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs. The significance of these compounds lies in their potential utility in methods for modulating RORγ activity in cells, particularly for treating diseases and disorders that could benefit from such modulation, including autoimmune and inflammatory conditions.

Another notable development is his patent involving heterocyclic compounds useful as modulators of TNF alpha. This patent discloses compounds of a defined formula and their salts, alongside methods for utilizing these compounds as modulators of TNFα. The applications of such compounds are particularly promising in the treatment of inflammatory and autoimmune diseases, underscoring Lu's role in addressing pressing medical challenges through innovative pharmaceutical solutions.

Career Highlights

Zhonghui Lu has significantly contributed to the pharmaceutical industry through his work at renowned companies. He has been associated with Bristol-Myers Squibb Company and Bristol-Myers Squibb Pharma Company, where he has played a vital role in research and development initiatives. His experiences at these leading organizations have helped hone his expertise in the creation of novel therapeutic agents.

Collaborations

Throughout his career, Lu has collaborated with notable colleagues, including Jingwu Duan and Bin Jiang. These partnerships illustrate the collaborative nature of innovation in the pharmaceutical field, as diverse expertise often leads to breakthroughs that single individuals may not achieve alone.

Conclusion

Zhonghui Lu's work exemplifies the impact of innovative thinking on healthcare and pharmaceutical development. Through his 19 patents and significant contributions to the modulation of disease-related pathways, Lu continues to advance the field, potentially transforming treatment paradigms for autoimmune and inflammatory disorders. His career reflects a commitment to scientific advancement and collaboration, paving the way for future innovations in medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…